Izrael - hebrejčina - Ministry of Health

tzamal bio-pharma ltd - busulphan 60 mg / 10 ml - solution for injection - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.

Izrael - hebrejčina - Ministry of Health

tzamal bio-pharma ltd - busulfan - תמיסה להזרקה - busulfan 60 mg / 10 ml - busulfan - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.

Izrael - hebrejčina - Ministry of Health

"אפוס טכנולוגיות רפואה וספורט בע""מ" - כלל האוכלוסיה - ערכת אפוס לאימון ושיקום יציבות ושליטה עצבית-שרירית

Izrael - hebrejčina - Ministry of Health

tzamal bio-pharma ltd - busulfan - תמיסה להזרקה - busulfan 60 mg / 10 ml - busulfan

Izrael - hebrejčina - Ministry of Health

beit-erez havat milatin ltd - ivermectin - תמיסה להזרקה - ivermectin 10 mg/ml

Izrael - hebrejčina - Ministry of Health

eliezer linevitz ltd. - ivermectin - פסטה - ivermectin 18.7 mg/g

Izrael - hebrejčina - Ministry of Health

euromar ltd - monensin as sodium - קפסולות - monensin as sodium 32.4 g

Izrael - hebrejčina - Ministry of Health

euromar ltd - monensin as sodium - קפסולות - monensin as sodium 32.4 g

Izrael - hebrejčina - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Izrael - hebrejčina - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob